In Re Defender Drug Stores, Inc.

126 B.R. 76, 1991 Bankr. LEXIS 1446, 1991 WL 57883
CourtUnited States Bankruptcy Court, D. Arizona
DecidedMarch 14, 1991
DocketBankruptcy Nos. 90-04885 PHX-RGM, through 90-04887 PHX-RGM, Adv. No. 91-128-PHX-RGM
StatusPublished
Cited by4 cases

This text of 126 B.R. 76 (In Re Defender Drug Stores, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Arizona primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Defender Drug Stores, Inc., 126 B.R. 76, 1991 Bankr. LEXIS 1446, 1991 WL 57883 (Ark. 1991).

Opinion

FINDINGS OF FACT AND CONCLUSIONS OF LAW DENYING THE RTC’S MOTION TO DISALLOW PAYMENT OF CONTINGENT ENHANCEMENT FEE TO LANDMARK COMMERCIAL CORPORATION

ROBERT G. MOOREMAN, Bankruptcy Judge.

At Phoenix, in this District, this matter having come before the Court for a hearing on March 5, 1991, on a motion filed by the Resolution Trust Corporation (the “RTC”), as conservator for Lincoln Savings & Loan Association, F.A., to disallow a 10% contingent enhancement fee payable to Landmark Commercial Corporation (“Landmark”) pursuant to a financing agreement previously approved by this Court, the Unsecured Creditors’ Committee (the “Committee”) having joined in the RTC’s motion, the parties having submitted and the Court having read written briefs with respect to the RTC’s motion, the Court having carefully considered the facts, the record in these proceedings, the arguments of counsel, and being otherwise fully advised in the premises, for good cause shown, the Court hereby enters the following findings of fact and conclusions of law pursuant to Rule 7052 of the Bankruptcy Rules and Rule 52(a) of the Federal Rules of Civil Procedure:

Findings of Fact

1. On May 10, 1990, Medicare-Glaser Corporation (“Medicare-Glaser”) filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. Pursuant to 11 U.S.C. §§ 1107 and 1108, Medicare-Glaser continued to operate its chain of retail drug and pharmaceutical stores as a debt- or-in-possession.

2. On May 11, 1990, the Court granted Medicare-Glaser’s motion to authorize post-petition financing with Landmark, and entered an emergency order authorizing Medicare-Glaser to obtain post-petition secured credit from Landmark. The Court entered a final order on July 18, 1990, approving Medicare-Glaser’s post-petition financing with Landmark.

3. Medicare-Glaser’s post-petition financing with Landmark terminated by its terms on November 10, 1990, at 5:00 p.m. C.S.T. and could not be extended unless agreed to in writing by Landmark. Prior to the November 10, 1990, termination date, Landmark notified Medicare-Glaser that it was in default of its obligations to *78 Landmark and that the post-petition financing would not be extended beyond the November 10, 1990, termination date. In addition, Landmark also advised Medicare-Glaser of its intent not to declare a default prior to the November 10, 1990, termination date, although grounds for a declaration of defaults existed.

4. Shortly before the scheduled termination of the post-petition financing (and in spite of the termination of the financing under a final order of this Court), the RTC nevertheless moved the Court to extend the November 10, 1990, termination date of the post-petition financing for a period of time to hold an auction sale of the Medicare-Glaser business or assets, thereby exposing Medicare-Glaser’s business or assets to “market” or “going concern” bids. The Committee joined in the RTC’s motion.

5. On November 9, 1990, Medicare-Glaser movéd the Court to extend the termination date of the post-petition financing to create the potential opportunity for a sale under 11 U.S.C. § 363 to realize “going concern” values and obtain “market” bids. Landmark agreed to extend the termination date of the post-petition financing, but only upon the Court’s authorization of certain specified conditions, including approval of the contingent Enhancement Fee (as defined below) as part of the extended financing.

6. Recognizing that Medicare-Glaser’s continuing operating losses would result in an erosion of Landmark’s collateral base, collateral mix and liquidation values, Landmark agreed to extend the termination date of the post-petition financing subject to specified credit “enhancers” being furnished by Medicare-Glaser to Landmark. One such “enhancer” called for a letter of credit to be posted for Landmark’s benefit, in exchange for which Landmark would extend the post-petition financing to March 10, 1991.'

7. In the event a letter of credit could not be furnished, Landmark agreed to extend the then-matured financing an additional 30 days so that the business and assets of Medicare-Glaser could be sold at auction under 11 U.S.C. § 363 as requested by the RTC and the Committee. Under this contingency, and as an inducement for Landmark to extend the post-petition financing beyond the November 10, 1990, termination date, Medicare-Glaser agreed to pay Landmark an additional payment equal to 10% of the gross consideration received by Medicare-Glaser for its business or assets in excess of the outstanding Landmark indebtedness (the “Enhancement Fee” under the “Agreement”). The Agreement specified that the Enhancement Fee, if any, would constitute part of the Landmark indebtedness and would be paid in cash concurrent with payment in full of the Landmark indebtedness. If the consideration received by Medicare-Glaser at an auction proved to be less than the Landmark indebtedness, however, Landmark would receive no Enhancement Fee and would look to its collateral and its rights for payment under the Court’s orders approving the post-petition financing.

8. Medicare-Glaser’s agreement with Landmark to pay the Enhancement Fee as an inducement for Landmark to extend the financing beyond the November 10, 1990, termination date was submitted to the Court for approval on November 9, 1990.

9. On November 13, 1990, after appropriate notice and a hearing (in which both the RTC and the Committee participated), the Court entered a final order (the “Extended Financing Order”) approving the Enhancement Fee as reasonable under the circumstances. The post-petition financing extension provided an opportunity for shared appreciation in the value of the estate, to the benefit of all creditors and parties-in-interest.

10. After careful consideration of the evidence presented to the Court at the November 13, 1990, hearing, and having had the opportunity to consider the testimony and judge the credibility of the witness (Rick J. Kratz) examined at that hearing, and affording appropriate weight to all such evidence, the Court made the following findings in the Extended Financing Order, which findings are hereby reaffirmed and incorporated herein by reference:

*79 a. Landmark was willing to extend the financing beyond its original maturity date only upon the express condition that, inter alia, Landmark have the right to receive the Enhancement Fee in the event Medicare-Glaser’s business or assets were sold under II U.S.C. § 363.

b.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Farmland Industries, Inc.
294 B.R. 855 (W.D. Missouri, 2003)
In Re Hatcher
202 B.R. 626 (E.D. Oklahoma, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
126 B.R. 76, 1991 Bankr. LEXIS 1446, 1991 WL 57883, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-defender-drug-stores-inc-arb-1991.